<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">diaendo</journal-id><journal-title-group><journal-title xml:lang="ru">Сахарный диабет</journal-title><trans-title-group xml:lang="en"><trans-title>Diabetes mellitus</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2072-0351</issn><issn pub-type="epub">2072-0378</issn><publisher><publisher-name>Endocrinology research centre</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14341/DM13479</article-id><article-id custom-type="elpub" pub-id-type="custom">diaendo-13479</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL STUDIES</subject></subj-group></article-categories><title-group><article-title>Оценка эффективности использования систем непрерывного мониторинга глюкозы, имеющих функции передачи данных, у детей с сахарным диабетом 1 типа по результатам трехлетнего дистанционного медицинского контроля</article-title><trans-title-group xml:lang="en"><trans-title>Effectiveness of Continuous Glucose Monitoring Systems with Data Transmission in Children with Type 1 Diabetes: A Three-Year Remote Follow-Up Study</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5578-5242</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кияев</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kiiaev</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кияев Алексей Васильевич, д.м.н. </p><p>620028, г. Екатеринбург, улица Репина, дом 3 </p></bio><bio xml:lang="en"><p>Alexey V. Kiiaev, MD, PhD</p><p>1 Repina street, 620028 Ekaterinburg</p></bio><email xlink:type="simple">thyroend@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1193-4856</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Промин</surname><given-names>И. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Promin</surname><given-names>I. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Промин Иван Александрович</p><p>Екатеринбург</p></bio><bio xml:lang="en"><p>Ivan A. Promin, MD</p><p>Ekaterinburg</p></bio><email xlink:type="simple">i-promin@yandex.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5180-6560</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Савельев</surname><given-names>Л. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Saveliev</surname><given-names>L. Y.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Савельев Леонид Иосифович, к.м.н.</p><p>Scopus Author ID: 55535477300</p><p>Екатеринбург</p></bio><bio xml:lang="en"><p>Leonid Y. Saveliev, MD, PhD</p><p>Scopus Author ID: 55535477300</p><p>Ekaterinburg</p></bio><email xlink:type="simple">sav7000@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Уральский государственный медицинский университет; Областная детская клиническая больница</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Ural State Medical University; Regional Children’s Clinical Hospital</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Уральский государственный медицинский университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Ural State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2026</year></pub-date><pub-date pub-type="epub"><day>01</day><month>10</month><year>2026</year></pub-date><volume>29</volume><issue>4</issue><fpage>338</fpage><lpage>344</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Кияев А.В., Промин И.А., Савельев Л.И., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Кияев А.В., Промин И.А., Савельев Л.И.</copyright-holder><copyright-holder xml:lang="en">Kiiaev A.V., Promin I.A., Saveliev L.Y.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.dia-endojournals.ru/jour/article/view/13479">https://www.dia-endojournals.ru/jour/article/view/13479</self-uri><abstract><sec><title>ЦЕЛЬ</title><p>ЦЕЛЬ. Провести анализ эффективности использования систем непрерывного мониторинга глюкозы (СНМГ) у детей с сахарным диабетом 1 типа (СД1), обеспеченных моделями с функцией передачи данных, а также влияния этих систем на основные параметры контроля углеводного обмена.</p></sec><sec><title>МАТЕРИАЛЫ И МЕТОДЫ</title><p>МАТЕРИАЛЫ И МЕТОДЫ. В настоящий фрагмент исследования включен массив данных СНМГ с функцией дистанционного мониторинга (ДМ), полученных у детей 4–17 лет с СД1, подключенных к профессиональному облачному кабинету врача (ПК), за период с сентября 2021 года по ноябрь 2024 года. Анализ эффективности использования СНМГ проводился на основании данных, импортированных из персонального компьютера (ПК), через 1, 2 и 3 года после начала обеспечения СНМГ, по следующим параметрам: активность датчика (АД) за предшествующие 2 недели; время в целом диапазоне (ВЦД) ≥70%; ВЦД &lt;50%. Критерием эффективности использования СНМГ служила АД ≥60%.</p></sec><sec><title>РЕЗУЛЬТАТЫ</title><p>РЕЗУЛЬТАТЫ. Количество пациентов, обеспеченных СНМГ и подключенных к ПК областного центра детской эндокринологии (ОЦДЭ), из всех детей с СД1: 1-й год — 716 из 1713 (41,8%); 2-й год — 1339 из 1838 (72,9%); 3-й год — 1264 из 1949 (64,9%). Доля детей, обеспеченных СНМГ с ДМ, но использующих их ненадлежащим образом (АД &lt;60%), значимо не изменилась за трехлетний период ДМК и составила 27,2%, 28,0% и 26,7% соответственно (p=0,684). Среди пациентов, активно использующих СНМГ (АД ≥60%): доля детей с хорошим гликемическим контролем (ВЦД ≥70%) к концу 3-го года значимо увеличилась по сравнению со 2-м годом и достигла 33,1%; доля пациентов с неудовлетворительным гликемическим контролем (ВЦД &lt;50%) значимо увеличилась с 27,1% до 38,1% ко 2-му году, затем значимо снизилась, но осталась на достаточно высоком уровне к концу 3-го года — 30,9%.</p></sec><sec><title>ЗАКЛЮЧЕНИЕ</title><p>ЗАКЛЮЧЕНИЕ. Результаты трехлетнего дистанционного мониторинга детей с СД1, обеспеченных СНМГ, демонстрируют ненадлежащее использование СНМГ более чем у 25% детей независимо от возраста, что приводит к невозможности адекватной интерпретации данных гликемии лечащим врачом и коррекции инсулинотерапии, что, в свою очередь, может вносить негативный вклад в показатели контроля углеводного обмена среди всех детей с СД1. Несмотря на значимое увеличение доли пациентов с хорошим гликемическим контролем, активно использующих СНМГ, к концу 3-го года дистанционного медицинского контроля (ДМК), сохраняется достаточно большая доля детей в группе риска по декомпенсации СД1 с плохим гликемическим контролем (30,9%).</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>AIM</title><p>AIM. To evaluate the effectiveness of continuous glucose monitoring (CGM) systems with data transmission in children with type 1 diabetes and to assess their impact on key glycemic control parameters.</p></sec><sec><title>MATERIALS AND METHODS</title><p>MATERIALS AND METHODS. This study included glucose datasets obtained from CGM systems with data transmission in children aged 4–17 years with type 1 diabetes who were connected to a physician’s professional cloud account between September 2021 and November 2024. The effectiveness of CGM use was assessed 1, 2, and 3 years after the initiation of CGM provision. The following parameters were analyzed: sensor activity during the preceding 2 weeks, time in range (TIR) ≥70%, and TIR &lt;50%. Effective CGM use was defined as sensor activity ≥60%.</p></sec><sec><title>RESULTS</title><p>RESULTS. Among all children with type 1 diabetes, the number of patients provided with CGM systems and connected to the professional cloud account was 716/1713 (41.8%) in year 1, 1339/1838 (72.9%) in year 2, and 1264/1949 (64.9%) in year 3. The proportion of children who used CGM inadequately (sensor activity &lt;60%) did not change significantly over the 3-year period of remote follow-up and was 27.2%, 28.0%, and 26.7%, respectively (p=0.684). Among active CGM users (sensor activity ≥60%), the proportion of children with TIR ≥70% increased significantly by the end of year 3 compared with year 2 and reached 33.1%. The proportion of patients with TIR &lt;50% increased significantly from 27.1% to 38.1% by year 2, then decreased significantly, but remained relatively high by the end of year 3 (30.9%).</p></sec><sec><title>CONCLUSION</title><p>CONCLUSION. Three-year remote follow-up of children with type 1 diabetes provided with CGM systems demonstrated inadequate CGM use in more than one quarter of patients regardless of age. This limited adequate interpretation of glycemic data by the treating physician and adjustment of insulin therapy and may have adversely affected glycemic control in the overall pediatric population with type 1 diabetes. Despite a significant increase in the proportion of active CGM users with TIR ≥70% by the end of year 3, a substantial proportion of children remained at risk of diabetes decompensation (30.9%).</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>сахарный диабет 1 типа</kwd><kwd>дети</kwd><kwd>системы непрерывного мониторинга глюкозы</kwd><kwd>дистанционный мониторинг</kwd><kwd>время в целевом диапазоне</kwd></kwd-group><kwd-group xml:lang="en"><kwd>type 1 diabetes</kwd><kwd>chidren</kwd><kwd>continuous glucose monitoring systems</kwd><kwd>remote monitoring</kwd><kwd>time in range</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Работа выполнена по инициативе авторов за счет бюджетных средств государственного автономного учреждения здравоохранения, на базе которого проводилось исследование, без привлечения дополнительного финансирования.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Adler AI, Coleman RL, Leal J, et al. Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91). Lancet. 2024;404(10448):145–155. doi: https://doi.org/10.1016/S0140-6736(24)00537-3</mixed-citation><mixed-citation xml:lang="en">Adler AI, Coleman RL, Leal J, et al. Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91). Lancet. 2024;404(10448):145–155. doi: https://doi.org/10.1016/S0140-6736(24)00537-3</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Лаптев Д.Н., Емельянов А.О., Андрианова Е.А., и др. Применение Flash-мониторинга глюкозы у детей с сахарным диабетом 1 типа в реальной клинической практике // Сахарный диабет. — 2021. — Т. 24. — № 6. — С. 504–510. doi: https://doi.org/10.14341/DM12817</mixed-citation><mixed-citation xml:lang="en">Laptev DN, Emelyanov AO, Andrianova EA, et al. The use of Flash glucose monitoring in children with type 1 diabetes mellitus in real clinical practice. Diabetes Mellitus. 2021;24(6):504–510. (In Russ.)] doi: https://doi.org/10.14341/DM12817</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Laffel LM, Kanapka LG, Beck RW, et al. Effect of Continuous Glucose Monitoring on Glycemic Control in Adolescents and Young Adults With Type 1 Diabetes: A Randomized Clinical Trial. JAMA. 2020;323(23):2388–2396. doi: https://doi.org/10.1001/jama.2020.6940</mixed-citation><mixed-citation xml:lang="en">Laffel LM, Kanapka LG, Beck RW, et al. Effect of Continuous Glucose Monitoring on Glycemic Control in Adolescents and Young Adults With Type 1 Diabetes: A Randomized Clinical Trial. JAMA. 2020;323(23):2388–2396. doi: https://doi.org/10.1001/jama.2020.6940</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Thabit H, Prabhu JN, Mubita W, et al. Use of Factory-Calibrated Real-time Continuous Glucose Monitoring Improves Time in Target and HbA1c in a Multiethnic Cohort of Adolescents and Young Adults With Type 1 Diabetes: The MILLENNIALS Study. Diabetes Care. 2020;43(10):2537–2543. doi: https://doi.org/10.2337/dc20-0736</mixed-citation><mixed-citation xml:lang="en">Thabit H, Prabhu JN, Mubita W, et al. Use of Factory-Calibrated Real-time Continuous Glucose Monitoring Improves Time in Target and HbA1c in a Multiethnic Cohort of Adolescents and Young Adults With Type 1 Diabetes: The MILLENNIALS Study. Diabetes Care. 2020;43(10):2537–2543. doi: https://doi.org/10.2337/dc20-0736</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Лаптев Д.Н., Безлепкина О.Б., Демина Е.С., и др. Результаты клинической апробации системы FreeStyle Libre у детей с сахарным диабетом 1 типа: улучшение гликемического контроля в сочетании со снижением риска тяжелой гипогликемии и диабетического кетоацидоза // Проблемы эндокринологии. — 2022. — Т. 68. — № 3. — С. 86–92. doi: https://doi.org/10.14341/probl12877</mixed-citation><mixed-citation xml:lang="en">Laptev DN, Bezlepkina OB, Demina ES, et al. Evaluation of FreeStyle Libre in pediatric t1dm: improved glycemic control, reduction in diabetic ketoacidosis and severe hypoglycemia. Problems of Endocrinology. 2022;68(3):86–92. (In Russ.)] doi: https://doi.org/10.14341/probl12877</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Sadeghi D. Improving Adherence to Treatment in Patients With Diabetes: Practical Strategies. Endocrinol Diabetes Metab. 2024;7(4):e00512. doi: https://doi.org/10.1002/edm2.512</mixed-citation><mixed-citation xml:lang="en">Sadeghi D. Improving Adherence to Treatment in Patients With Diabetes: Practical Strategies. Endocrinol Diabetes Metab. 2024;7(4):e00512. doi: https://doi.org/10.1002/edm2.512</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Дедов И.И., Шестакова М.В., Викулова О.К., и др. Эпидемиология и ключевые клинико-терапевтические показатели сахарного диабета в Российской Федерации в разрезе стратегических целей Всемирной организации здравоохранения // Сахарный диабет. — 2025. — Т. 28. — № 1. — С. 4–17. doi: https://doi.org/10.14341/DM13292</mixed-citation><mixed-citation xml:lang="en">Dedov II, Shestakova MV, Vikulova OK, et al. Epidemiology and key clinical and therapeutic indicators of diabetes mellitus in Russian Federation according to the World Health Organization’s strategy goals. Diabetes Mellitus. 2025;28(1):4–17. (In Russ.)] doi: https://doi.org/10.14341/DM13292</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Лаптев Д.Н. Сахарный диабет 1 типа у детей: впереди взрослая жизнь // Сахарный диабет. — 2025. — Т. 28. — № 1. — С. 18–25. doi: https://doi.org/10.14341/DM13252</mixed-citation><mixed-citation xml:lang="en">Laptev DN. Type 1 diabetes in children: adulthood ahead. Diabetes Mellitus. 2025;28(1):18–25. (In Russ.)] doi: https://doi.org/10.14341/DM13252</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Foster NC, Beck RW, Miller KM, et al. State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016–2018. Diabetes Technol Ther. 2019;21(2):66–72. doi: https://doi.org/10.1089/dia.2018.0384</mixed-citation><mixed-citation xml:lang="en">Foster NC, Beck RW, Miller KM, et al. State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016–2018. Diabetes Technol Ther. 2019;21(2):66–72. doi: https://doi.org/10.1089/dia.2018.0384</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Hermann JM, Miller KM, Hofer SE, et al. The Transatlantic HbA1c gap: differences in glycaemic control across the lifespan between people included in the US T1D Exchange Registry and those included in the German/Austrian DPV registry. Diabet Med. 2020;37(5):848–855. doi: https://doi.org/10.1111/dme.14148</mixed-citation><mixed-citation xml:lang="en">Hermann JM, Miller KM, Hofer SE, et al. The Transatlantic HbA1c gap: differences in glycaemic control across the lifespan between people included in the US T1D Exchange Registry and those included in the German/Austrian DPV registry. Diabet Med. 2020;37(5):848–855. doi: https://doi.org/10.1111/dme.14148</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Šumník Z, Pavlíková M, Pomahačová R, et al. Use of continuous glucose monitoring and its association with type 1 diabetes control in children over the first 3 years of reimbursement approval: Population data from the ČENDA registry. Pediatr Diabetes. 2021;22(3):439–447. doi: https://doi.org/10.1111/pedi.13184</mixed-citation><mixed-citation xml:lang="en">Šumník Z, Pavlíková M, Pomahačová R, et al. Use of continuous glucose monitoring and its association with type 1 diabetes control in children over the first 3 years of reimbursement approval: Population data from the ČENDA registry. Pediatr Diabetes. 2021;22(3):439–447. doi: https://doi.org/10.1111/pedi.13184</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Telo GH, Volkening LK, Butler DA, Laffel LM. Salient characteristics of youth with type 1 diabetes initiating continuous glucose monitoring. Diabetes Technol Ther. 2015;17(6):373–378. doi: https://doi.org/10.1089/dia.2014.0290</mixed-citation><mixed-citation xml:lang="en">Telo GH, Volkening LK, Butler DA, Laffel LM. Salient characteristics of youth with type 1 diabetes initiating continuous glucose monitoring. Diabetes Technol Ther. 2015;17(6):373–378. doi: https://doi.org/10.1089/dia.2014.0290</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Tilden DR, French B, Datye KA, Jaser SS. Disparities in Continuous Glucose Monitor Use Between Children With Type 1 Diabetes Living in Urban and Rural Areas. Diabetes Care. 2024;47(3):346–352. doi: https://doi.org/10.2337/dc23-1564</mixed-citation><mixed-citation xml:lang="en">Tilden DR, French B, Datye KA, Jaser SS. Disparities in Continuous Glucose Monitor Use Between Children With Type 1 Diabetes Living in Urban and Rural Areas. Diabetes Care. 2024;47(3):346–352. doi: https://doi.org/10.2337/dc23-1564</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Khadilkar A, Oza C. Glycaemic Control in Youth and Young Adults: Challenges and Solutions. Diabetes Metab Syndr Obes. 2022;15:121–129. doi: https://doi.org/10.2147/DMSO.S304347</mixed-citation><mixed-citation xml:lang="en">Khadilkar A, Oza C. Glycaemic Control in Youth and Young Adults: Challenges and Solutions. Diabetes Metab Syndr Obes. 2022;15:121–129. doi: https://doi.org/10.2147/DMSO.S304347</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Monaghan M, Bryant BL, Inverso H, et al. Young Children with Type 1 Diabetes: Recent Advances in Behavioral Research. Curr Diab Rep. 2022;22(6):247–256. doi: https://doi.org/10.1007/s11892-022-01465-0</mixed-citation><mixed-citation xml:lang="en">Monaghan M, Bryant BL, Inverso H, et al. Young Children with Type 1 Diabetes: Recent Advances in Behavioral Research. Curr Diab Rep. 2022;22(6):247–256. doi: https://doi.org/10.1007/s11892-022-01465-0</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
